A full marketing authorisation has been granted by the authorities in Italy for the treatment of moderate to severe spasticity in Multiple Sclerosis patients who have not responded adequately to other anti-spasticity medications.
This licence to market Sativex in Italy comes by way of the publication of Sativex in the Italian Official Journal (Gazzetta Ufficiale) and reflects that regulatory, pricing and reimbursement approvals are now in place for an expected commercial launch in September by GW's partner, Almirall.
The reimbursed price of the medicine granted by the authorities in Italy is consistent with the reimbursed Sativex price in Spain.
At 8:39am: [LON:GWP] GW Pharmaceuticals share price was +1.75p at 52p
Story provided by StockMarketWire.com